๐ Clinical Trials – An Overview
By Dr. Sk Sabir Rahaman, MBBS, MD (Pharmacology), DFM(Family Medicine), FCFM, CCEBDM, CCLSD
๐น What Are Clinical Trials?
A clinical trial is a scientifically controlled, ethically approved study in human participants designed to evaluate a new drug’s:
-
Safety
-
Efficacy
-
Tolerability
-
Optimal dosage
๐ Clinical trials are mandatory after preclinical testing in animals.
They require prior approval from regulatory authorities:
-
DCGI (India)
-
FDA (USA)
-
EMA (Europe)
Permission to begin human studies is granted through an Investigational New Drug (IND) application, which includes preclinical safety data, manufacturing details, and trial protocols.
๐น Ethical Principles in Clinical Trials
All trials must follow bioethics principles to protect human subjects:
| Principle | Meaning |
|---|---|
| Autonomy | Respect participants’ right to make informed decisions |
| Beneficence | Maximize potential benefits |
| Non-maleficence | “Do no harm” – minimize risks |
| Justice | Ensure fair participant selection and equitable distribution of risks/benefits |
✅ Ethics Committee (IEC/IRB) approval is mandatory before starting a trial.
In India, Clinical Trial Registry of India (CTRI) registration is mandatory before starting any human clinical trial.
๐น Clinical Trial Registration in India
-
In India, registration of all clinical trials in the CTRI (Clinical Trial Registry – India) is mandatory.
-
CTRI is a free, online public record system under the ICMR (Indian Council of Medical Research) and the National Institute of Medical Statistics (NIMS).
-
Since June 15, 2009, the DCGI (Drug Controller General of India) has made CTRI registration compulsory for:
-
Regulatory drug trials (new drugs, biologics, vaccines)
-
Academic / investigator-initiated trials
-
Interventional trials (devices, procedures, AYUSH interventions)
-
-
Even post-marketing surveillance trials and bioequivalence studies must be registered.
Why CTRI Registration Matters
-
Transparency – makes trial details publicly accessible.
-
Ethical Compliance – aligns with ICMR guidelines & Declaration of Helsinki.
-
Avoids duplication – prevents unnecessary repetition of similar trials.
-
Publication requirement – leading journals (ICMJE, PubMed indexed) demand trial registration number (CTRI/XXXX/XX/XXXX).
-
Regulatory Oversight – helps DCGI and Ethics Committees monitor trial status.
๐ So the regulatory flow in India is:
Preclinical → DCGI approval (IND) → Ethics Committee approval → CTRI Registration → Trial initiation.
๐น Phases of Clinical Trials
Phase 0 (Microdosing Studies) – Exploratory
-
Participants: 6–15 volunteers/patients
-
Dose: Sub-therapeutic (<1/100th active dose)
-
Objective: Study PK/PD and target engagement (not efficacy)
-
Outcome: Early “go/no-go” decision to save cost and risk
-
Tools: AMS, PET imaging, biomarker analysis
Example: Using microdose PET imaging of a new anticancer drug to see if it reaches tumor tissue.
Phase I (Human Safety & Dosage)
-
Participants: 10–100 healthy volunteers (or patients in oncology trials)
-
Objective: Safety, tolerability, maximum tolerated dose (MTD), PK/PD data
-
Design: Open-label, non-randomized
-
Setting: Research units with close monitoring
Phase II (Therapeutic Exploration)
-
Participants: 50–500 patients with the target disease
-
Objective: Explore efficacy, define dose range, continue PK/PD + safety evaluation
-
Design: Randomized, controlled, often single-blind
-
Setting: Conducted in a few (3–4) medical centers
Phase III (Therapeutic Confirmation)
-
Participants: 1,000–5,000+ diverse patients
-
Objective: Confirm efficacy, detect uncommon ADRs, study interactions, long-term safety
-
Design: Multicenter, randomized, double-blind, comparative
-
Outcome: If successful → regulatory approval & marketing license
Gold standard for evidence-based medicine.
Phase IV (Postmarketing Surveillance)
-
Conducted after approval
-
Objective: Detect rare/long-term ADRs, study real-world effectiveness, evaluate in special populations (children, elderly, pregnancy)
-
Methods: Cohort studies, registries, spontaneous ADR reporting
-
Legal Requirement: Manufacturers must submit Periodic Safety Update Reports (PSURs) to DCGI/CDSCO.
๐น Other Clinical Research Designs (Beyond RCTs)
| Study Type | Purpose |
|---|---|
| Case–Control | Retrospective, compare diseased vs non-diseased |
| Cohort | Prospective, follow exposed vs unexposed |
| Meta-analysis | Pool multiple studies for stronger conclusions |
๐น Why Is This Important?
-
Trials are the bridge between lab research and real-world medicine.
-
Builds foundation for rational, ethical prescribing.
-
Future doctors may:
-
Recruit patients into trials
-
Monitor ADRs/SAEs
-
Interpret trial data for practice
-
-
Encourages awareness of regulatory science & pharmacovigilance.
๐ Summary Table
| Phase | Participants | Key Focus | Design | Outcome |
|---|---|---|---|---|
| 0 | 6–15 | PK/PD at microdose | Exploratory, non-therapeutic | Early go/no-go |
| I | 10–100 | Safety, tolerability, PK/PD | Open-label | MTD & safe dose |
| II | 50–500 | Efficacy, dose-response | Randomized, single-blind | Proof of concept |
| III | 1000–5000+ | Confirm efficacy, ADRs | RCT, double-blind, multicenter | Regulatory approval |
| IV | Post-approval | Rare ADRs, real-world data | Observational, PSURs | Long-term safety |
๐ Visit My Website for Articles & other Free PDFs and Resources
Comments
Post a Comment